359 related articles for article (PubMed ID: 29601839)
1. Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.
Desai KG; Obayashi H; Colandene JD; Nesta DP
J Pharm Sci; 2018 Jul; 107(7):1773-1786. PubMed ID: 29601839
[TBL] [Abstract][Full Text] [Related]
2. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
3. Japanese regulatory system for approval of off-label drug use: evaluation of safety and effectiveness in literature-based applications.
Shimazawa R; Ikeda M
Clin Ther; 2012 Oct; 34(10):2104-16. PubMed ID: 23036337
[TBL] [Abstract][Full Text] [Related]
4. Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
Rokuda M; Matsumaru N; Tsukamoto K
Clin Ther; 2018 Feb; 40(2):284-295. PubMed ID: 29361305
[TBL] [Abstract][Full Text] [Related]
5. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
6. Closing the drug lag for new drug submission and review in Japan: An industry perspective.
Poirier AF
Clin Pharmacol Ther; 2015 Nov; 98(5):486-8. PubMed ID: 26239646
[TBL] [Abstract][Full Text] [Related]
7. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical excipient development: the need for preclinical guidance.
Baldrick P
Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
[TBL] [Abstract][Full Text] [Related]
9. Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications.
Haque A; Daniel S; Maxwell T; Boerstoel M
Clin Ther; 2017 Apr; 39(4):675-685. PubMed ID: 28392076
[TBL] [Abstract][Full Text] [Related]
10. Delays in new drug applications in Japan and industrial R&D strategies.
Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
[TBL] [Abstract][Full Text] [Related]
11. Impact of Postapproval Evidence Generation on the Biopharmaceutical Industry.
Milne CP; Cohen JP; Felix A; Chakravarthy R
Clin Ther; 2015 Aug; 37(8):1852-8. PubMed ID: 26143223
[TBL] [Abstract][Full Text] [Related]
12. Accelerated approval of oncology products: the food and drug administration experience.
Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
[TBL] [Abstract][Full Text] [Related]
13. Drug development and registration in Japan: threshold of transition.
Currie WJ
J Clin Pharmacol; 1993 Feb; 33(2):100-8. PubMed ID: 8440757
[TBL] [Abstract][Full Text] [Related]
14. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
[TBL] [Abstract][Full Text] [Related]
15. Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals.
Thompson DO
Crit Rev Ther Drug Carrier Syst; 1997; 14(1):1-104. PubMed ID: 9043816
[TBL] [Abstract][Full Text] [Related]
16. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of extemporaneously compounded immediate-release capsules with premixed excipients, based on the biopharmaceutics classification system (BCS) of the drugs.
Pinheiro VA; Danopoulos P; Demirdjian L; Nogueira RJ; Dubois F
Int J Pharm Compd; 2013; 17(5):424-31. PubMed ID: 24459788
[TBL] [Abstract][Full Text] [Related]
18. [Regulatory aspects of biosimilars. Myths and facts].
Schneider CK; Weise M
Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
[TBL] [Abstract][Full Text] [Related]
19. [Contribution of pharmacology for new drug application in Japan].
Suzuki-Nishimura T; Toyoshima S; Uyama Y; Yamada H; Hosoki R; Fujimori K; Nagao T
Nihon Yakurigaku Zasshi; 2002 Sep; 120(3):187-94. PubMed ID: 12271514
[TBL] [Abstract][Full Text] [Related]
20. Vendor qualification for pharmaceutical excipients--GMP requirements and approach.
Patel KT; Chotal NP
Pharmazie; 2010 Nov; 65(11):783-90. PubMed ID: 21155382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
